Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.
The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues. Tango has entered strategic collaborations with major pharmaceutical partners to advance these programs, most notably a multi-asset agreement with GSK to discover and develop DNA damage response inhibitors and a partnership with Merck focused on novel synthetic lethal targets in oncology. These alliances provide access to additional computational tools, screening libraries and global development expertise.
Founded in 2019 as a spin-out from Dana-Farber Cancer Institute and Harvard Medical School, Tango Therapeutics is headquartered in Cambridge, Massachusetts, near one of the world’s leading biopharma clusters. The management team combines scientific founders with broad drug development experience, enabling the company to rapidly translate genetic insights into translational programs. Tango has assembled an advisory board of academic and industry experts to guide target selection and clinical strategy.
With its concentrated focus on synthetic lethality, Tango Therapeutics seeks to address unmet needs in solid tumors and hematologic cancers driven by specific genetic lesions. The company is advancing its pipeline through IND-enabling studies and early clinical trials, aiming to validate its approach of pairing genomic profiling with highly selective therapies. Tango’s platform is designed to uncover novel treatment modalities that could extend the benefits of precision oncology to patient populations beyond those served by current standard-of-care agents.
AI Generated. May Contain Errors.
Free TNGX Stock Alerts